Famciclovir Dosing for Herpes Simplex Virus Infections

Introduction to Famciclovir Use

The US regulatory agencies do not approve or recommend famciclovir for suppressive therapy of herpes labialis (cold sores) 1, 2

Famciclovir has received approval for episodic treatment of herpes labialis, with a single-dose regimen of 1500 mg or a twice-daily regimen of 750 mg for 1 day, demonstrating reduced median healing times compared to placebo 2, 3
Both regimens show efficacy when initiated early in the prodromal phase, with median healing times of 4.0-4.4 days compared to 6.2 days for placebo 3

The Centers for Disease Control and Prevention (CDC) and other guideline societies approve famciclovir for suppressive therapy of recurrent genital herpes, at a dose of 250 mg twice daily 1, 2
This suppressive dose has been studied and shown to extend the time to recurrence of genital herpes 1, 2

The American Academy of Dermatology and other medical societies advise against extrapolating genital herpes dosing to herpes labialis due to differences in regulatory approvals, disease patterns, and treatment goals 1, 2
Despite long-term antiviral use, HSV-1 resistance rates remain low, at less than 0.5% in immunocompetent hosts, according to the Infectious Diseases Society of America 2
The World Health Organization (WHO) and other global health authorities emphasize that timing is critical for episodic therapy, with treatment initiation during the prodromal phase necessary for maximum efficacy 1, 2